Source:http://linkedlifedata.com/resource/pubmed/id/19203723
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2009-2-10
|
| pubmed:abstractText |
Reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation (HCT) allowed the existence of an allogeneic cell-mediated antitumor effect in metastatic colorectal cancer (mCRC) to be explored. We report on 39 patients with progressing mCRC treated with different RIC regimens in a multicenter clinical trial of the European Bone Marrow Transplantation Group. Disease status at transplant was progressive disease (PD) in 31 patients (80%), stable disease (SD) in 6 (15%), and partial response (PR) in 2 (5%). All patients engrafted (median donor T cell chimerism of 90% at day +60). Transplant-related morbidities were limited. Grades II-IV acute graft-versus-host disease (aGVHD) occurred in 14 patients (35%) and chronic GVHD (cGVHD) in 9 patients (23%). Transplant-related mortality occurred in 4 patients (10%). The best tumor responses were: 1 complete response (CR) (2%), 7 PR (18 %), and 10 SD (26%), giving an overall disease control in 18 of 39 patients (46%). Allogeneic HCT after RIC is feasible; the collected results compared favorably in terms of tumor response with those observed using conventional approaches beyond second-line therapies. The study of an allogeneic cell based therapy in less advanced patients is warranted.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1523-6536
|
| pubmed:author |
pubmed-author:AgliettaMassimoM,
pubmed-author:BarkholtLisbethL,
pubmed-author:BertolderoGiovanniG,
pubmed-author:CapaldiAntonioA,
pubmed-author:CaravelliDanielaD,
pubmed-author:CicconeGiovanninoG,
pubmed-author:DemirerTannerT,
pubmed-author:EBMT Solid Tumor Working Party,
pubmed-author:HentschkePatrikP,
pubmed-author:LeoneFrancescoF,
pubmed-author:MinottoColudiaC,
pubmed-author:NiederwieserDietgerD,
pubmed-author:OmazicBrigittaB,
pubmed-author:RingdénOlleO,
pubmed-author:SchiancaFabrizio CarnevaleFC
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
326-35
|
| pubmed:meshHeading |
pubmed-meshheading:19203723-Adolescent,
pubmed-meshheading:19203723-Adult,
pubmed-meshheading:19203723-Aged,
pubmed-meshheading:19203723-Child,
pubmed-meshheading:19203723-Child, Preschool,
pubmed-meshheading:19203723-Colorectal Neoplasms,
pubmed-meshheading:19203723-Female,
pubmed-meshheading:19203723-Graft vs Host Disease,
pubmed-meshheading:19203723-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:19203723-Humans,
pubmed-meshheading:19203723-Immunotherapy, Adoptive,
pubmed-meshheading:19203723-Male,
pubmed-meshheading:19203723-Middle Aged,
pubmed-meshheading:19203723-Neoplasm Metastasis,
pubmed-meshheading:19203723-Transplantation Conditioning,
pubmed-meshheading:19203723-Whole-Body Irradiation,
pubmed-meshheading:19203723-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience.
|
| pubmed:affiliation |
Division of Medical Oncology, Department of Oncological Sciences, Institute for Cancer Research and Treatment, Candiolo and University of Torino Medical School, Turin, Italy.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|